US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Mirum Pharmaceuticals Inc (NASDAQ:MIRM). stock reached an all-time high of 55.25 USD, marking a significant milestone for the biopharmaceutical company with a market capitalization of $2.64 billion. According to InvestingPro data, the company boasts impressive revenue growth of 62.33% over the last twelve months. This peak reflects the company’s robust performance over the past year, during which its stock has appreciated by 33.91%. Mirum Pharmaceuticals’ focus on developing therapies for rare liver diseases has likely contributed to investor confidence and the stock’s upward trajectory. The surge to this all-time high underscores the market’s positive outlook, supported by analysts’ consensus recommendation of "Strong Buy" and a potential upside to their target prices. InvestingPro subscribers can access 11 additional exclusive insights and a comprehensive Pro Research Report that provides deep-dive analysis of MIRM’s financial health and growth prospects.
In other recent news, Mirum Pharmaceuticals reported strong second-quarter 2025 financial results, with total revenues reaching $127.8 million, marking a 64% increase compared to the same period in 2024. The earnings per share for the quarter were -$0.12, significantly outperforming the forecasted -$0.33. This revenue figure also exceeded expectations of $107.36 million, resulting in a 19.02% surprise. Following these positive results, H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $80, maintaining a Buy rating. Similarly, JMP Securities increased its price target to $81, keeping a Market Outperform rating. The company also exceeded expectations with its Livmarli and bile acid sales, leading management to adjust its 2025 guidance to between $490 million and $510 million, which represents a 48% year-over-year growth at the midpoint. These developments reflect the company’s strong performance and have influenced analysts’ positive outlooks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.